Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Mesalamine

Mesalamine

Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
It works by reducing inflammation in the gastrointestinal tract.
PubCompare.ai helps researchers optimize their Mesalamine studies by providing AI-driven comparisons of protocols from literature, preprints, and patents.
This enhances reproducibility and accuracy, ensuring researchers get the most reliable and effective results for their Mesalamine research.
Streamline your Mesalamine studies with the power of PubCompare.ai's innovative platform.

Most cited protocols related to «Mesalamine»

1
Rosiglitazone for Ulcerative Colitis: A Placebo-Controlled Trial
Cited 179 times
Data for this study were acquired from a recently completed placebo-controlled randomized trial of rosiglitazone for mild to moderately active ulcerative colitis (clinicaltrials.gov #NCT00065065) which has been described in greater detail previously.7 (link) The trial used a slight modification of the Mayo score to assess disease activity (Table 1). Specifically, the bleeding component as described in the Mayo index was modified such that a score of 3 required both visible blood in 50% or more of bowel movements and at least some bowel movements with blood alone.
The study included 105 patients with mild to moderately active disease defined as a total DAI score of 4 to 10, inclusively. Patients were randomized in a 1:1 ratio to receive either rosiglitazone 4 mg or placebo twice daily for 12 weeks. Disease activity was measured at randomization and every four weeks thereafter until week 12, however lower endoscopy was only completed at week 0 and week 12, such that only a partial Mayo score (9 point scale that excludes the endoscopic appearance of the mucosa) could be calculated at the interim visits. In the very early accrual period of the study, a follow-up visit was included at week 2. Without knowledge of the response rates in either arm, the Data and Safety Monitoring Board (DSMB) requested that the week 2 follow-up evaluation be eliminated with the hopes of minimizing the placebo response rate and maximizing recruitment and retention.6 (link), 8 (link), 9 (link) Eighteen patients completed the week 2 follow-up visit.
During the course of the study, patients could be treated with other conventional medications used to treat active ulcerative colitis including mesalamine, oral corticosteroids, immunomodulators, or topical therapies (mesalamine or corticosteroids) at stable doses. Use of corticosteroids at doses greater than 20mg per day of prednisone or the equivalent was an exclusion criterion. Steroid tapering was not permitted during the study.
In anticipation of this sub-study, at each visit we also included questions about change in disease activity compared to the previous visit and compared to the randomization visit on a global seven-point scale (Table 2). The choices included much better, moderately better, a little better, unchanged, a little worse, moderately worse, and much worse. Patients also graded their current disease activity at each visit on a 6 point Likert scale – perfect, very good (minimal symptoms), good (only mild symptoms), moderately active, moderately severe, or severe. Data on quality of life were measured with the Inflammatory Bowel Disease Questionnaire (IBDQ) authored by Dr. Jan Irvine under license from McMaster University, Hamilton, Canada.10 (link)
Lewis J.D., Chuai S., Nessel L., Lichtenstein G.R., Aberra F.N, & Ellenberg J.H. (2008). Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. Inflammatory bowel diseases, 14(12), 1660-1666.
Publication 2008
Adrenal Cortex Hormones BLOOD Clinical Trials Data Monitoring Committees Defecation Endoscopy Endoscopy, Gastrointestinal Immunologic Adjuvants Inflammatory Bowel Diseases Mesalamine Mucous Membrane Patients Pharmaceutical Preparations Placebos Prednisone Retention (Psychology) Rosiglitazone Steroids Ulcerative Colitis
2
Pediatric Ulcerative Colitis Prospective Study
Cited 8 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2019
Biopsy Child Diagnosis Esophagogastroduodenoscopy Ethics Committees, Research Feces Gene Expression Immunologic Adjuvants Leukocyte L1 Antigen Complex Mesalamine Microbiome North American People Pediatric ulcerative colitis Pentasa Pharmaceutical Preparations Rectum RNA, Ribosomal, 16S Safety Therapeutics Tumor Necrosis Factor-alpha
3
HIV-1 Viral Suppression and Mesalamine
Cited 8 times
Enrolled subjects on continuous suppressive ART were randomized to receive either mesalamine or matching placebo for 12 weeks, followed by a 12 week crossover period on the alternative arm. The primary outcome was the change in the percent activated (CD38+ HLA-DR+) CD8+ T cells at week 12. Consenting subjects also participated in a serial rectal biopsy sub-study to evaluate the effects of mesalamine in the GALT.
Subjects were recruited from the University of California, San Francisco [UCSF] between February, 2011 and June, 2012 with the last date of follow-up occurring in December, 2012. Chronically HIV-infected adults maintaining plasma HIV RNA levels below the limit of detection of the locally available clinical threshold for ≥1 year on stable ART and with persistent CD4+ T cell counts <350 cells/mm3 were eligible. Detectable episodes of viremia <500 copies/ml were allowed in the prior year if they were flanked by confirmed undetectable values. Patients were ineligible if they experienced an increase in CD4+ T cell count >100 cells/mm3 in the last year; reported <90% adherence to ART; had any serious acute illness in the preceding 3 months; were pregnant or breastfeeding; or had any of the following laboratory abnormalities: absolute neutrophil count <1,000 cells/mm3, platelet count <50,000 cells/mm3, hemoglobin <8 mg/dL, creatinine clearance <40 mL/minute, or serum transaminases >2.5x the upper limit of normal. For the endothelial function studies, as nitroglycerin is administered, any Viagra-like drug within 72 hours of the study was prohibited. Changes in doses of lipid lowering medication or anti-hypertensive medication were also not permitted less than 90 days prior to study entry or during the study.
The study was approved by the institutional review board at UCSF and all subjects provided written informed consent (IRB #: 10–010123; Clinical Trials #: NCT01090102). The protocol for this trial and supporting checklist are available as S1 Protocol and S1 CONSORT Checklist.
Somsouk M., Dunham R.M., Cohen M., Albright R., Abdel-Mohsen M., Liegler T., Lifson J., Piatak M., Gorelick R., Huang Y., Wu Y., Hsue P.Y., Martin J.N., Deeks S.G., McCune J.M, & Hunt P.W. (2014). The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial. PLoS ONE, 9(12), e116306.
Publication 2014
Adult Antihypertensive Agents Biopsy CD4 Positive T Lymphocytes CD8-Positive T-Lymphocytes Cells Congenital Abnormality Creatinine Endothelium Hemoglobin HLA-DR Antigens Lipids Mesalamine Neutrophil Nitroglycerin Patients Pharmaceutical Preparations Placebos Plasma Platelet Counts, Blood Rectum Serum Transaminases Viagra Viremia
4
Cirrhosis Surgical Outcomes in Veterans
Cited 7 times
We performed a retrospective cohort study of patients with cirrhosis using well-phenotyped, longitudinal data from the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) cohort, which contains data from 128 VHA hospitals. The derivation of the VOCAL cohort has been previously described;12 (link) in brief, it contains medical data on over 129,000 patients with cirrhosis identified between 2008 and 2016, and has been used for numerous natural history studies of chronic liver disease.13 –19 We merged VOCAL with the Veterans Affairs Surgical Quality Improvement Program (VASQIP) dataset.20 (link) This dataset contains prospectively adjudicated data on VHA surgical procedures, including pre-operative, intraoperative, and post-operative data with validated reliability.21 (link) After the VOCAL-VASQIP data merge, we included all patients at least 18 years of age with cirrhosis, defined using a validated algorithm based on International Classification of Diseases (ICD) codes.22 (link) We excluded patients who did not receive a surgical procedure of interest (hepatic surgeries, minor surgeries, or those with accepted low risk; detailed below), those who received liver transplantation prior to surgery, and those who had a pre-operative ASA classification of 5 due to exceptional circumstances of these cases and associated very high morbidity and mortality. We also excluded patients with insufficient pre-operative laboratory data to compute the MELD-Na and MRS, using a window of 30 days prior to surgery. Finally, surgery categories in which fewer than 50 procedures were performed were excluded given limited statistical power to draw inferences associated with mortality; this resulted in the exclusion of central nervous system (CNS) surgeries.
Mahmud N., Fricker Z., Hubbard R.A., Ioannou G.N., Lewis J.D., Taddei T.H., Rothstein K.D., Serper M., Goldberg D.S, & Kaplan D.E. (2020). Novel Risk Prediction Models for Post-Operative Mortality in Patients with Cirrhosis. Hepatology (Baltimore, Md.), 73(1), 204-218.
Publication 2020
Liver Liver Cirrhosis Liver Diseases Liver Transplantations Mesalamine Minor Surgical Procedures Neurosurgical Procedures Operative Surgical Procedures Patients Veterans
5
Inflammatory Bowel Disease and ESRD Risk
Cited 6 times
We collected data on patient demographics (age, sex, place of residence, and income level) and on the medications used for IBD treatment, including 5-aminosalicylic acid (ASA), corticosteroids, immunomodulators (azathioprine/6-mercaptopurine and methotrexate), and anti-tumor necrosis factor (TNF)-α agents (infliximab, adalimumab and golimumab). Medication use was defined as all relevant medications prescribed within 1 year of the diagnosis of IBD. We also collected information on comorbidities identified with ICD-10 codes, including hypertension (ICD-10 codes: I10-13 and I15, and medications for treating hypertension), DM (E11-14, and medications for treating DM), dyslipidemia (E78, and medications for treating dyslipidemia), congestive heart failure (I50), ischemic heart disease (I20-I25), hyperuricemia, and gout (E79 and M10). The definitions of these comorbidities were validated previously[19 (link)]. The metabolically healthy condition was defined as the absence of DM, hypertension, and dyslipidemia. An underlying disease was defined as the presence of at least one of the following: DM, hypertension, dyslipidemia, congestive heart failure, ischemic heart disease, hyperuricemia, and gout.
The primary endpoint was newly diagnosed ESRD during follow-up. ESRD was detected with the combination of an ICD-10 code (N18-19, Z49, Z94.0, and Z99.2) and a V code assigned to patients with CKD that required hemodialysis (V001), peritoneal dialysis (V003), or a kidney transplantation (V005), as defined previously[19 (link)]. All patients that underwent dialysis or a kidney transplantation were enrolled in the RID program; therefore, we could identify and analyze data for all patients with ESRD in the study population. Both the IBD cohort and the matched control cohort were followed-up for the development of ESRD until December 2015. During follow-up, patients without newly developed ESRD were censored on the last day of follow-up or the date of death.
Park S., Chun J., Han K.D., Soh H., Choi K., Kim J.H., Lee J., Lee C., Im J.P, & Kim J.S. (2018). Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study. World Journal of Gastroenterology, 24(42), 4798-4808.
Publication 2018
Adalimumab Adrenal Cortex Hormones Anti-Anxiety Agents Azathioprine Congestive Heart Failure Dialysis Dyslipidemias golimumab Gout Hemodialysis High Blood Pressures Hyperuricemia Immunologic Adjuvants Infliximab Kidney Failure, Chronic Kidney Transplantation Mercaptopurine Mesalamine Methotrexate Myocardial Ischemia Patients Peritoneal Dialysis Pharmaceutical Preparations TNF protein, human

Most recents protocols related to «Mesalamine»

1
Ingestible Device for Ulcerative Colitis Treatment
Not available on PMC !

Example 12

As a proof of concept, the patient population of this study is patients that (1) have moderate to severe ulcerative colitis, regardless of extent, and (2) have had an insufficient response to a previous treatment, e.g., a conventional therapy (e.g., 5-ASA, corticosteroid, and/or immunosuppressant) or a FDA-approved treatment. In this placebo-controlled eight-week study, patients are randomized. All patient undergo a colonoscopy at the start of the study (baseline) and at week 8. Patients enrolled in the study are assessed for clinical status of disease by stool frequency, rectal bleeding, abdominal pain, physician's global assessment, and biomarker levels such as fecal calprotectin and hsCRP. The primary endpoint is a shift in endoscopy scores from Baseline to Week 8. Secondary and exploratory endpoints include safety and tolerability, change in rectal bleeding score, change in abdominal pain score, change in stool frequency, change in partial Mayo score, change in Mayo score, proportion of subjects achieving endoscopy remission, proportion of subjects achieving clinical remission, change in histology score, change in biomarkers of disease such as fecal calprotectin and hsCRP, level of adalimumab in the blood/tissue/stool, change in cytokine levels (e.g., TNFα, IL-6) in the blood and tissue.

FIG. 72 describes an exemplary process of what would occur in clinical practice, and when, where, and how the ingestible device will be used. Briefly, a patient displays symptoms of ulcerative colitis, including but not limited to: diarrhea, bloody stool, abdominal pain, high c-reactive protein (CRP), and/or high fecal calprotectin. A patient may or may not have undergone a colonoscopy with diagnosis of ulcerative colitis at this time. The patient's primary care physician refers the patient. The patient undergoes a colonoscopy with a biopsy, CT scan, and/or MRI. Based on this testing, the patient is diagnosed with ulcerative colitis. Most patients are diagnosed with ulcerative colitis by colonoscopy with biopsy. The severity based on clinical symptoms and endoscopic appearance, and the extent, based on the area of involvement on colonoscopy with or without CT/MRI is documented. Treatment is determined based on diagnosis, severity and extent.

For example, treatment for a patient that is diagnosed with ulcerative colitis is an ingestible device programmed to release a single bolus of a therapeutic agent, e.g., 40 mg adalimumab, in the cecum or proximal to the cecum. Prior to administration of the treatment, the patient is fasted overnight and is allowed to drink clear fluids. Four hours after swallowing the ingestible device, the patient can resume a normal diet. An ingestible device is swallowed at the same time each day. The ingestible device is not recovered.

In some embodiments, there may be two different ingestible devices: one including an induction dose (first 8 to 12 weeks) and a different ingestible device including a different dose or a different dosing interval.

In some examples, the ingestible device can include a mapping tool, which can be used after 8 to 12 weeks of induction therapy, to assess the response status (e.g., based on one or more of the following: drug level, drug antibody level, biomarker level, and mucosal healing status). Depending on the response status determined by the mapping tool, a subject may continue to receive an induction regimen or maintenance regimen of adalimumab.

In different clinical studies, the patients may be diagnosed with Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the cecum, or in both the cecum and transverse colon.

In different clinical studies, the patients may be diagnosed with illeocolonic Crohn's disease and the ingestible devices (including adalimumab) can be programmed to release adalimumab in the late jejunum or in the jejunum and transverse colon.

US11857669B2. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices (2024-01-02). BIORA THERAPEUTICS, INC. [US]. Inventors: Mitchell Lawrence Jones [US], Sharat Singh [US], Christopher Loren Wahl [US], Harry Stylli [US].
Patent 2024
Abdominal Pain Adalimumab Adrenal Cortex Hormones Biological Markers Biopsy BLOOD Cecum Colonoscopy C Reactive Protein Crohn Disease Cytokine Diarrhea Diet Endoscopy Endoscopy, Gastrointestinal Feces Homo sapiens Immunoglobulins Immunosuppressive Agents Jejunum Leukocyte L1 Antigen Complex Medical Devices Mesalamine Mucous Membrane Neoadjuvant Therapy Patient Care Management Patients Pharmaceutical Preparations Placebos Primary Care Physicians Safety Therapeutics Tissues Transverse Colon Treatment Protocols Tumor Necrosis Factor-alpha Ulcerative Colitis X-Ray Computed Tomography
2
Retrospective Study of Advanced Therapies for IBD
This was a retrospective claim-based cohort study that utilized longitudinal claims data from the HealthCore Integrated Research Database® (HIRD®) from January 1, 2016 to August 31, 2019. The HIRD® contains data from January 2006 on patient enrollment, inpatient and outpatient medical care, prescription, and health care utilization. It is a large longitudinal medical and pharmacy claims database of health plan members comprising all regions of the US.
The data were accessed and used in full compliance with the relevant provisions of the Health Insurance Portability and Accountability Act. The study was conducted under the research provisions of Privacy Rule 45 CFR 164.514(e). Researchers’ access to claims data was limited to data stripped of identifiers to ensure confidentiality. An Institutional Review Board did not review the study since only this limited data set was accessed. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemiology Practices as well as legal and regulatory requirements.
Adult patients aged ≥ 18 years with CD (International Classification of Diseases, 10th Revision, Clinical Modification [ICD-10-CM] diagnosis codes: K50.x) or UC (ICD-10-CM diagnosis codes: K51.x) who initiated an advanced therapy during the index period of July 1, 2016 through August 31, 2018 were included in the study. Index date was defined as the first observed occurrence of a claim (medical or pharmacy) for any eligible advanced therapy during the index period. For patients who started more than one therapy, only the earliest one observed was used. Included patients were enrolled in commercial, Medicare Advantage, or Medicare Supplemental plus Part D insurance plans for ≥ 6 months before the index date (pre-index period) and ≥ 12 months after index date (follow-up period). Eligible patients were required to have ≥ 2 medical claims for CD or UC from a provider of any specialty at least seven days apart during the study period, of which ≥ 1 claim occurred during the pre-index period.
In this study, advanced therapies for CD included TNFi (adalimumab, certolizumab, infliximab) and non-TNFi (natalizumab, ustekinumab, vedolizumab). For UC, advanced therapies included TNFi (adalimumab, golimumab, infliximab), non-TNFi (vedolizumab; ustekinumab as a potential switcher but not index drug), and other therapies (tofacitinib). Conventional therapies included 5-aminosalicylic acid derivatives (mesalazine and sulfasalazine) and immunosuppressants (azathioprine, methotrexate, mycophenolate, cyclosporine, tacrolimus, 6-mercaptopurine).
Patients were excluded if they had claims for ≥ 1 advanced therapy during the 6-month pre-index period to identify new initiators of advanced therapy. Patients who had evidence for other autoimmune diseases including psoriasis, lupus, ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis (defined as ≥ 2 claims on different dates for the same disease) were also excluded in order to avoid misclassification of the estimated response rate (e.g., related to non-adherence) due to multiple indications.
Gibble T.H., Naegeli A.N., Grabner M., Isenberg K., Shan M., Teng C.C, & Curtis J.R. (2023). Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States. BMC Gastroenterology, 23, 63.
Publication 2023
Adalimumab Adult Ankylosing Spondylitis Arthritis, Psoriatic Autoimmune Diseases Azathioprine Care, Ambulatory Certolizumab Pegol Cyclosporine derivatives Diagnosis Ethics Committees, Research golimumab Health Planning Immunosuppressive Agents Infantile Neuroaxonal Dystrophy Infliximab Inpatient Insurance, Medigap Lupus Vulgaris Mercaptopurine Mesalamine Methotrexate Natalizumab Patient Acceptance of Health Care Patients Pharmaceutical Preparations Psoriasis Rheumatoid Arthritis Sulfasalazine Tacrolimus Therapeutics tofacitinib Ustekinumab vedolizumab
3
Incarcerated Patient with Recurrent C. difficile Colitis
A 31-year-old incarcerated AA male complained of hematochezia and fever requiring admission to the hospital and was diagnosed with Clostridium difficile colitis. CT scan and colonoscopy showed left-sided colitis. Following treatment with oral vancomycin, outpatient colonoscopy was consistent with residual proctosigmoiditis. Through SDM, he was started on mesalamine enemas but had difficulty retaining them and decision was made to start on UST for ease of dosing and avoidance of per-rectum therapies per patient preference. The UST was infused at the clinic during a scheduled visit. He missed multiple doses due to inconsistent transport to clinic for nurse-led administration of medication. He was then released from custody and off all therapy until developing C. difficile infection requiring hospitalization. He was treated with vancomycin and then resumed on PO and PR mesalamine as an outpatient. However, upon reincarceration with questionable access to medication, he developed worsening symptoms and was started on sulfasalazine. Repeat colonoscopy showed Mayo 3 pancolitis with pathology confirming moderate inflammation. He resumed UST therapy with a standard loading dose given at a clinic appointment and 90 mg SC every 8 weeks consistently while incarcerated. The patient has since been released from the detention center and has a steady job. He has been in frequent contact with the PCMH and the behavioral health social worker who assists him in coming to appointments and receiving his medication in a timely fashion from the specialty pharmacy. Clinically, he is doing well and is planned for endoscopic evaluation shortly once his insurance is valid. Additional biochemical evaluation is pending given the cost associated with self-pay laboratory studies.
Barbina S., Romano J, & Forster E. (2023). Challenges in the Management of and Biologic Use in Incarcerated Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360, 5(2), otad002.
Publication 2023
Administration, Oral Clostridium difficile Colitis Colonoscopy Endoscopy Enema Fever Hematochezia Hospitalization Infection Inflammation Males Mesalamine Nurses Outpatients Patients Pharmaceutical Preparations Proctosigmoiditis Sulfasalazine Therapeutics Vancomycin Worker, Social X-Ray Computed Tomography
4
DSS-Induced Colitis and Probiotic Treatment
Six-week-old male SPF C57BL/6 mice (weight, 18–20 g) were purchased from Shanghai SLRC Laboratory Animal Co. Ltd. (Shanghai, China). The mice were housed at a constant temperature of 23 ± 2°C with a 12-h dark/light cycle and given ad libitum access to standard chow and water at all times. All mice were allowed at least 1 week to adapt to the experimental environment before conducting the following experiments. The experimental procedures were performed in accordance with the institutional and governmental regulations on the ethical use of experimental animals.
The mice were randomly divided into 11 groups of eight (Figure 1). The Control group was given free access to sterile water and fed a normal diet for the whole experimental period (12 days). The DSS group was given free access to 2.5% DSS-containing drinking water for the first 7 days and then fed normal diet and normal water for the next 5 days of the experiment. The DSS-treated mouse groups of L. plantarum AR113 and its seven bshmutant derivatives were administered the corresponding strains (0.2 mL containing 5 × 109CFU/mL) once a day by gavage from day 5 to day 12. The 5-ASA group of DSS-treated mice was administered 5-ASA (0.2mL) once a day by gavage from day 5 to day 12.
Feng X., Bu Z., Tang H., Xia Y., Song X., Ai L, & Wang G. (2023). Bile salt hydrolase of Lactiplantibacillus plantarum plays important roles in amelioration of DSS-induced colitis. iScience, 26(3), 106196.
Publication 2023
Animals, Laboratory derivatives Diet Males Mesalamine Mice, House Mice, Inbred C57BL Sterility, Reproductive Strains Tube Feeding
5
Mesalamine Enteric Soluble Tablets and Intestinal Microbiota Transplantation for Ulcerative Colitis

Patients in the two groups received four mesalamine enteric soluble tablets (Sunflower Pharmaceutical Group Jiamusi Luling Pharmaceutical Co., Ltd., State Pharmacopoeia H19980148) orally, thrice daily. The treatment duration was 30d.

Patients in the research group additionally received IMT. ①Donor selection: Adults under 30 years old from a standard fecal bacteria bank, with a healthy lifestyle, good dietary habits, no bad habits such as smoking and drinking, no chronic diseases, no infectious diseases, no chronic diarrhea, constipation, irritable bowel disease, and no history of antibiotic or probiotic and other drug supplements use in the past 3 months were selected. ②Preparation of flora: Fecal bacteria were prepared by the manual method: 200 g of donor stool was collected early in the morning, and 50 g of stool was dissolved in 250 mL of saline, stirred, and filtered through filter sieves of 2-, 1-, 0.5- and 0.25-mm diameter. The supernatant was removed after centrifugation, and the precipitate was resuspended with saline and stored in a −80 °C refrigerator. ③Fecal bacteria transplantation. The frozen bacterial solution was thawed and rewarmed in a 37 °C water bath, 50 g of stool in 250 mL of saline. Transscopic intestinal implantation is adopted. The IMT was performed once a week, with a treatment duration of 30 d. During the treatment, the in-hospital medical staff provided dietary and lifestyle guidance to the patients.

Wang Z., Yang L, & Sun S. (2023). Effect of Intestinal Microbiota Transplantation on Intestinal Flora and Inflammatory Factor Levels in Patients with Ulcerative Colitis. Infection and Drug Resistance, 16, 1183-1191.
Publication 2023
Adult Antibiotics Bacteria Bath Centrifugation Communicable Diseases Constipation Diarrhea Diet Dietary Supplements Disease, Chronic Donors Donor Selection Fecal Microbiota Transplantation Feces Freezing Helianthus annuus Inflammatory Bowel Diseases Intestines Medical Staff, Hospital Mesalamine Ovum Implantation Patients Personnel, Hospital Pharmaceutical Preparations Probiotics Saline Solution

Top products related to «Mesalamine»

1
Dextran sulfate sodium (dss) by MP Biomedicals
Sourced in United States, France, Germany, China, Canada, United Kingdom, Australia, Japan, Panama, Philippines
The DSS is a laboratory instrument designed for the separation and analysis of molecules and particles in complex samples. It utilizes a specialized technique called differential sedimentation to achieve precise separation and characterization of the components within a sample. The core function of the DSS is to provide accurate and reliable data on the size, distribution, and concentration of the analytes present, without interpretation or extrapolation on its intended use.
2
5 asa by Merck Group
Sourced in United States, United Kingdom, Italy, Germany
5-ASA is a laboratory reagent used in analytical and diagnostic applications. It is a chemical compound with the formula C7H7NO3 that serves as a key component in various analytical procedures. The core function of 5-ASA is to facilitate specific chemical reactions and analyses, but a detailed description of its intended use would require further information that is not currently available.
3
5 aminosalicylic acid by Merck Group
Sourced in United States, Germany
5-aminosalicylic acid is a chemical compound used in various laboratory applications. It is a crystalline solid with a white or off-white appearance. The compound has a molecular formula of C₇H₇NO₃ and a molar mass of 153.14 g/mol. 5-aminosalicylic acid is commonly used as a building block in organic synthesis and as a research reagent in various scientific fields.
4
5 aminosalicylic acid 5 asa by Merck Group
Sourced in United States
5-aminosalicylic acid (5-ASA) is a chemical compound commonly used in laboratory settings. It is a crystalline, white to off-white powder with a molecular formula of C7H7NO3. 5-ASA is a derivative of salicylic acid and is known for its anti-inflammatory properties. This product can be used as a chemical intermediate or research reagent in various applications, but no further details on its intended use are provided.
5
Mesalazine by Merck Group
Sourced in United States
Mesalazine is a pharmaceutical product used as a laboratory reagent. It is a colorful, crystalline solid that is commonly used in various analytical and experimental procedures.
6
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
7
Methanol by Merck Group
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
8
Hexadecyltrimethylammonium bromide by Merck Group
Sourced in United States, Germany, Switzerland, Italy, France, China, Poland, Spain
Hexadecyltrimethylammonium bromide is a cationic surfactant commonly used in laboratory applications. It functions as a detergent and emulsifier, with the ability to solubilize and disperse various compounds.
9
Glacial acetic acid by Merck Group
Sourced in Germany, United States, United Kingdom, India, Italy, Spain, Singapore, France, Brazil, Canada, Belgium, Switzerland, Japan, China, Australia, Sao Tome and Principe, Chile, Malaysia, Macao, Finland, Ireland, Sweden, Netherlands, Portugal
Glacial acetic acid is a colorless, odorous, and corrosive liquid used as a laboratory reagent. It has a chemical formula of CH3COOH and a concentration of 99.7% or higher. Glacial acetic acid is commonly used in various analytical and research applications, serving as a solvent, catalyst, and pH modifier.
10
Formic acid by Merck Group
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.

More about "Mesalamine"

Mesalamine, also known as 5-aminosalicylic acid (5-ASA) or mesalazine, is a medication commonly used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.
It works by reducing inflammation in the gastrointestinal tract, which can help alleviate symptoms and promote healing.
Mesalamine is a derivative of salicylic acid and belongs to the class of drugs called aminosalicylates.
It is thought to exert its anti-inflammatory effects through various mechanisms, including inhibition of prostaglandin and leukotriene synthesis, scavenging of free radicals, and modulation of the immune response.
In addition to its use in the treatment of inflammatory bowel diseases, mesalamine has also been investigated for its potential benefits in other conditions, such as rheumatoid arthritis and certain types of cancer.
Research is ongoing to explore the full extent of mesalamine's therapeutic applications.
When it comes to studying mesalamine, researchers often utilize various experimental techniques and protocols, such as cell culture assays, animal models, and clinical trials.
To optimize these studies and ensure reproducibility and accuracy, researchers can leverage platforms like PubCompare.ai, which provides AI-driven comparisons of protocols from literature, preprints, and patents.
By using PubCompare.ai, researchers can streamline their mesalamine research and access the most reliable and effective protocols, enhancing the overall quality and impact of their work.
The platform's innovative features, such as the ability to compare protocols across different sources and identify the most optimal approaches, can be invaluable in advancing our understanding of mesalamine and its potential therapeutic applications.